Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvecaltamide in Parkinson's disease tremor
NCT05642442Phase 2Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Dec 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Placebo with Suvecaltamide (2 arms). Primary endpoint: Essential Tremor Rating Scale Composite Outcome at 17 weeks. Started Dec 2022; status: completed.
02
Drugs
suvecaltamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05642442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05642442.